

David S Dickens

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1831159/publications.pdf>

Version: 2024-02-01

36
papers

857
citations

687363

13
h-index

477307

29
g-index

36
all docs

36
docs citations

36
times ranked

1128
citing authors

#	ARTICLE	IF	CITATIONS
1	Barriers to Pediatric Oncologist Enrollment of Adolescents and Young Adults on a Cross-Network National Clinical Trials Network Supportive Care Cancer Clinical Trial. <i>Journal of Adolescent and Young Adult Oncology</i> , 2022, 11, 117-121.	1.3	8
2	Characterizing academic performance in pediatric acute lymphoblastic leukemia with population-based achievement tests. <i>Cancer Reports</i> , 2022, 5, e1560.	1.4	2
3	Wearable Monitors Facilitate Exercise in Adult and Pediatric Stem Cell Transplant. <i>Exercise and Sport Sciences Reviews</i> , 2021, 49, 205-212.	3.0	1
4	Reducing sedated lumbar punctures in pediatric patients with acute lymphoblastic leukemia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29272.	1.5	4
5	SARS-CoV-2 in Childhood Cancer in 2020: A Disease of Disparities. <i>Journal of Clinical Oncology</i> , 2021, 39, 3778-3788.	1.6	28
6	Choice architecture for young adult blood donor recruitment – a feasibility study. <i>Psychology, Health and Medicine</i> , 2021, , 1-6.	2.4	0
7	Does Body Mass Index (BMI) during Maintenance Influence Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL)? Results from COG-AALL03N1. <i>Blood</i> , 2021, 138, 213-213.	1.4	3
8	WD Repeat Domain 1 (<i>WDR1</i>) Deficiency Presenting as a Cause of Infantile Inflammatory Bowel Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 71, e113-e117.	1.8	3
9	Understanding the Barriers to Pediatric Oncologist Engagement and Accrual to Clinical Trials in National Cancer Institute-Designated Community Oncology Research Programs. <i>JCO Oncology Practice</i> , 2020, 16, e1060-e1066.	2.9	6
10	Barriers to Medication Access in Pediatric Oncology in the United States. <i>Journal of Pediatric Hematology/Oncology</i> , 2019, 41, 286-288.	0.6	10
11	Comparison of self-report and electronic monitoring of 6MP intake in childhood ALL: a Children's Oncology Group study. <i>Blood</i> , 2017, 129, 1919-1926.	1.4	32
12	Medication prior authorization in pediatric hematology and oncology. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26339.	1.5	20
13	Mercaptopurine Ingestion Habits, Red Cell Thioguanine Nucleotide Levels, and Relapse Risk in Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group Study AALL03N1. <i>Journal of Clinical Oncology</i> , 2017, 35, 1730-1736.	1.6	26
14	Low Enrollment of Adolescents and Young Adults Onto Cancer Trials: Insights From the Community Clinical Oncology Program. <i>Journal of Oncology Practice</i> , 2016, 12, e388-e395.	2.5	63
15	Exploring Readiness to Engage in Difficult Discussions with Adolescents Living with Advanced Cancer. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S115-S116.	2.0	3
16	KRAS insertion mutations are oncogenic and exhibit distinct functional properties. <i>Nature Communications</i> , 2016, 7, 10647.	12.8	15
17	6-Mercaptopurine (6MP) Intake during Maintenance for Childhood Acute Lymphoblastic Leukemia (ALL) - a Comparison of Self-Report and Electronic Monitoring: A Report from the Children's Oncology Group (COG) Study AALL03N1. <i>Blood</i> , 2015, 126, 82-82.	1.4	3
18	6MP adherence in a multiracial cohort of children with acute lymphoblastic leukemia: a Children's Oncology Group study. <i>Blood</i> , 2014, 124, 2345-2353.	1.4	164

#	ARTICLE	IF	CITATIONS
19	Factors associated with nonadherence to oral 6-mercaptopurine (6MP) in children with acute lymphoblastic leukemia (ALL): A report from Children's Oncology Group (COG) study AALL03N1.. Journal of Clinical Oncology, 2014, 32, 10013-10013.	1.6	2
20	Impact of 6 Mercaptopurine (6MP) Pill-Taking Habits on Adherence, Thioguanine Nucleotide (TGN) Levels and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): Results from a Children's Oncology Group (COG) Study (AALL03N1). Blood, 2014, 124, 369-369.	1.4	0
21	Biochemical and Functional Analysis of Novel KRAS Insertions in MPN and Other Cancers. Blood, 2014, 124, 2207-2207.	1.4	0
22	Surveillance of Hospital-Acquired Central Line-Associated Bloodstream Infections in Pediatric Hematology-Oncology Patients Lessons Learned, Challenges Ahead. Infection Control and Hospital Epidemiology, 2013, 34, 315-320.	1.8	17
23	Nonadherence to Oral Mercaptopurine and Risk of Relapse in Hispanic and Non-Hispanic White Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2012, 30, 2094-2101.	1.6	269
24	Nonadherence to Oral 6-Mercaptopurine (6MP) in a Multi-Ethnic Cohort of Children with Acute Lymphoblastic Leukemia (ALL) and Its Impact On Relapse – a Children's Oncology Group (COG) Study (AALL03N1). Blood, 2012, 120, 882-882.	1.4	2
25	Comparing pediatric deaths with and without hospice support. Pediatric Blood and Cancer, 2010, 54, 746-750.	1.5	34
26	“I Wouldn't Do That if I Were You” The Power of Regret When Treating the Incurable. Journal of Clinical Oncology, 2009, 27, 1528-1528.	1.6	1
27	Building Competence in Pediatric End-Of-Life Care. Journal of Palliative Medicine, 2009, 12, 617-622.	1.1	16
28	Therapeutic Strategies for Targeting Mononuclear Phagocytes in Cancer. Journal of Pediatric Hematology/Oncology, 2009, 31, 14-17.	0.6	3
29	Characteristics of pediatric chemotherapy medication errors in a national error reporting database. Cancer, 2008, 112, 445-446.	4.1	1
30	Impact of Computerized Prescriber Order Entry on the Incidence of Adverse Drug Events in Pediatric Inpatients. Pediatrics, 2008, 122, 678-678.	2.1	0
31	New Roles for Mononuclear Phagocytes in Cancer Biology. Journal of Pediatric Hematology/Oncology, 2008, 30, 584-591.	0.6	6
32	Primum Non Nocere. JAMA Pediatrics, 2006, 160, 1185.	3.0	0
33	Successful Treatment of an Unresectable Choroid Plexus Carcinoma in a Patient With Li-Fraumeni Syndrome. Journal of Pediatric Hematology/Oncology, 2005, 27, 46-49.	0.6	11
34	Effect of Combined Cyclooxygenase-2 and Matrix Metalloproteinase Inhibition on Human Sarcoma Xenografts. Journal of Pediatric Hematology/Oncology, 2003, 25, 709-714.	0.6	17
35	Cyclooxygenase-2 Expression Does Not Correlate With Outcome in Osteosarcoma or Rhabdomyosarcoma. Journal of Pediatric Hematology/Oncology, 2003, 25, 282-285.	0.6	38
36	Cyclooxygenase-2 Expression in Pediatric Sarcomas. Pediatric and Developmental Pathology, 2002, 5, 356-364.	1.0	49